-$0.25 EPS Expected for TAIWAN LIPOSOME/S (NASDAQ:TLC) This Quarter

Brokerages predict that TAIWAN LIPOSOME/S (NASDAQ:TLC) will post earnings per share (EPS) of ($0.25) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for TAIWAN LIPOSOME/S’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.24). TAIWAN LIPOSOME/S reported earnings per share of ($0.12) during the same quarter last year, which would suggest a negative year over year growth rate of 108.3%. The company is expected to report its next quarterly earnings report on Monday, November 25th.

According to Zacks, analysts expect that TAIWAN LIPOSOME/S will report full-year earnings of ($0.89) per share for the current financial year, with EPS estimates ranging from ($0.94) to ($0.78). For the next year, analysts anticipate that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.54) to ($0.96). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for TAIWAN LIPOSOME/S.

Several research analysts have commented on the company. Zacks Investment Research downgraded TAIWAN LIPOSOME/S from a “buy” rating to a “hold” rating in a research note on Saturday, July 13th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of TAIWAN LIPOSOME/S in a report on Monday, May 20th. Finally, Robert W. Baird assumed coverage on TAIWAN LIPOSOME/S in a report on Thursday, June 20th. They set an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $9.50.

A hedge fund recently bought a new stake in TAIWAN LIPOSOME/S stock. Millennium Management LLC purchased a new stake in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned 0.34% of TAIWAN LIPOSOME/S as of its most recent filing with the Securities & Exchange Commission. 2.94% of the stock is owned by institutional investors and hedge funds.

NASDAQ:TLC traded up $0.46 during trading on Friday, reaching $5.48. The company’s stock had a trading volume of 100 shares, compared to its average volume of 634. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.69 and a current ratio of 2.69. The company has a market capitalization of $161.22 million and a price-to-earnings ratio of -11.66. TAIWAN LIPOSOME/S has a 12 month low of $5.00 and a 12 month high of $11.00. The company has a 50 day simple moving average of $5.22.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Read More: Why is momentum important to successful trading?

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit